Chapter title |
Alternative Donor/Unrelated Donor Transplants for the β-Thalassemia and Sickle Cell Disease
|
---|---|
Chapter number | 5 |
Book title |
Gene and Cell Therapies for Beta-Globinopathies
|
Published in |
Advances in experimental medicine and biology, November 2017
|
DOI | 10.1007/978-1-4939-7299-9_5 |
Pubmed ID | |
Book ISBNs |
978-1-4939-7297-5, 978-1-4939-7299-9
|
Authors |
Courtney D. Fitzhugh, Allistair Abraham, Matthew M. Hsieh, Fitzhugh, Courtney D., Abraham, Allistair, Hsieh, Matthew M. |
Abstract |
Considerable progress with respect to donor source has been achieved in allogeneic stem cell transplant for patients with hemoglobin disorders, with matched sibling donors in the 1980s, matched unrelated donors and cord blood sources in the 1990s, and haploidentical donors in the 2000s. Many studies have solidified hematopoietic progenitors from matched sibling marrow, cord blood, or mobilized peripheral blood as the best source-with the lowest graft rejection and graft versus host disease (GvHD), and highest disease-free survival rates. For patients without HLA-matched sibling donors, but who are otherwise eligible for transplant, fully allelic matched unrelated donor (8/8 HLA-A, B, C, DRB1) appears to be the next best option, though an ongoing study in patients with sickle cell disease will provide data that are currently lacking. There are high GvHD rates and low engraftment rates in some of the unrelated cord transplant studies. Haploidentical donors have emerged in the last decade to have less GvHD; however, improvements are needed to increase the engraftment rate. Thus the decision to use unrelated cord blood units or haploidentical donors may depend on the institutional expertise; there is no clear preferred choice over the other. Active research is ongoing in expanding cord blood progenitor cells to overcome the limitation of cell dose, including the options of small molecule inhibitor compounds added to ex vivo culture or co-culture with supportive cell lines. There are inconsistent data from using 7/8 or lower matched unrelated donors. Before routine use of these less matched donor sources, work is needed to improve patient selection, conditioning regimen, GvHD prophylaxis, and/or other strategies. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 4 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 26 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 6 | 23% |
Student > Master | 3 | 12% |
Student > Ph. D. Student | 3 | 12% |
Student > Doctoral Student | 2 | 8% |
Other | 2 | 8% |
Other | 4 | 15% |
Unknown | 6 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 31% |
Agricultural and Biological Sciences | 2 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
Biochemistry, Genetics and Molecular Biology | 1 | 4% |
Immunology and Microbiology | 1 | 4% |
Other | 4 | 15% |
Unknown | 8 | 31% |